Literature DB >> 26678062

Toll-like receptors, triggering receptor expressed on myeloid cells family members and receptor for advanced glycation end-products in allergic airway inflammation.

Sannette C Hall1, Devendra K Agrawal1,2,3.   

Abstract

Asthma is a chronic disorder of the airways characterized by cellular infiltration, airway hyper-responsive and airway inflammation. Innate immune cells are the first line of defense against endogenous and exogenous signals in the airways and as such possess a diverse array of pattern recognition receptors. Toll-like receptors are crucial sentinels which when activated, can either promote or ameliorate the inflammatory response in predisposed individuals. The recently discovered triggering receptor expressed on myeloid cells family members are emerging mediators of inflammation. These receptors are believed to modulate inflammatory responses by collaborating with classic PRRs. Endogenous signals like HMGB-1, signaling through the receptor for advanced glycation end products, also promotes inflammation, however, its contribution to inflammation in the airways is not well known. Here, we discuss the role of each receptor in airway inflammation and highlight potential synergistic mechanisms, which contribute to disease pathogenesis in allergic asthma.

Entities:  

Keywords:  Allergic airway inflammation; DAP12; HMGB-1; NF-κB; RAGE; TLR; TREM; asthma

Mesh:

Substances:

Year:  2016        PMID: 26678062      PMCID: PMC4955846          DOI: 10.1586/17476348.2016.1133303

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  100 in total

1.  Increased levels of HMGB-1 and endogenous secretory RAGE in induced sputum from asthmatic patients.

Authors:  Tetsuya Watanabe; Kazuhisa Asai; Hiroki Fujimoto; Hidenori Tanaka; Hiroshi Kanazawa; Kazuto Hirata
Journal:  Respir Med       Date:  2010-10-30       Impact factor: 3.415

2.  Activation of human basophils by combined toll-like receptor- and FcεRI-triggering can promote Th2 skewing of naive T helper cells.

Authors:  Jolien Suurmond; Jeroen N Stoop; Felice Rivellese; Aleida M Bakker; Tom W J Huizinga; René E M Toes
Journal:  Eur J Immunol       Date:  2013-11-13       Impact factor: 5.532

3.  TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1.

Authors:  Qisheng Peng; Shikha Malhotra; James A Torchia; William G Kerr; K Mark Coggeshall; Mary Beth Humphrey
Journal:  Sci Signal       Date:  2010-05-18       Impact factor: 8.192

Review 4.  Toll-like receptors and B cells: functions and mechanisms.

Authors:  Claire M Buchta; Gail A Bishop
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

5.  Triggering receptor expressed on myeloid cells-1 as a new therapeutic target during inflammatory diseases.

Authors:  Marc Derive; Frédéric Massin; Sébastien Gibot
Journal:  Self Nonself       Date:  2010-07-02

6.  Modulation of the triggering receptor expressed on myeloid cells-1 pathway during pneumonia in rats.

Authors:  Sébastien Gibot; Corentine Alauzet; Frédéric Massin; Nassira Sennoune; Gilbert C Faure; Marie-Christine Béné; Alain Lozniewski; Pierre-Edouard Bollaert; Bruno Lévy
Journal:  J Infect Dis       Date:  2006-08-29       Impact factor: 5.226

7.  HMGB1 binding to receptor for advanced glycation end products enhances inflammatory responses of human bronchial epithelial cells by activating p38 MAPK and ERK1/2.

Authors:  Yue Liang; Changchun Hou; Jinliang Kong; Hanchun Wen; Xiaowen Zheng; Lihong Wu; Hong Huang; Yiqiang Chen
Journal:  Mol Cell Biochem       Date:  2015-04-11       Impact factor: 3.396

8.  Src homology domain 2-containing protein-tyrosine phosphatase-1 (SHP-1) binds and dephosphorylates G(alpha)-interacting, vesicle-associated protein (GIV)/Girdin and attenuates the GIV-phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway.

Authors:  Yash Mittal; Yelena Pavlova; Mikel Garcia-Marcos; Pradipta Ghosh
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

9.  Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia.

Authors:  Luke Hatchwell; Adam Collison; Jason Girkin; Kristy Parsons; Junyao Li; Jie Zhang; Simon Phipps; Darryl Knight; Nathan W Bartlett; Sebastian L Johnston; Paul S Foster; Peter A B Wark; Joerg Mattes
Journal:  Thorax       Date:  2015-06-24       Impact factor: 9.139

Review 10.  Toll-like receptors in antiviral innate immunity.

Authors:  Sandra N Lester; Kui Li
Journal:  J Mol Biol       Date:  2013-12-03       Impact factor: 5.469

View more
  6 in total

Review 1.  Triggering receptor expressed on myeloid cells and 5'adenosine monophosphate-activated protein kinase in the inflammatory response: a potential therapeutic target.

Authors:  Finosh G Thankam; Matthew F Dilisio; Kaitlin A Dougherty; Nicholas E Dietz; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-06-13       Impact factor: 4.473

Review 2.  Triggering receptor expressed on myeloid cells in the pathogenesis of periodontitis: potential novel treatment strategies.

Authors:  Courtney P Rudick; Takanari Miyamoto; Melissa S Lang; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2017-10-20       Impact factor: 4.473

Review 3.  Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19.

Authors:  Rajesh Rajaiah; Kandahalli V Abhilasha; Mysore A Shekar; Stefanie N Vogel; Bannikuppe S Vishwanath
Journal:  Cell Immunol       Date:  2020-10-15       Impact factor: 4.868

4.  TLR7/8 in the Pathogenesis of Parkinson's Disease.

Authors:  Michela Campolo; Alessia Filippone; Carmelo Biondo; Giuseppe Mancuso; Giovanna Casili; Marika Lanza; Salvatore Cuzzocrea; Emanuela Esposito; Irene Paterniti
Journal:  Int J Mol Sci       Date:  2020-12-09       Impact factor: 5.923

5.  AXL Inhibits Proinflammatory Factors to Relieve Rheumatoid Arthritis Pain by Regulating the TLR4/NF-κB Signaling Pathway.

Authors:  Guangzan Zhou; Hang Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-09       Impact factor: 2.650

Review 6.  TREM-1; Is It a Pivotal Target for Cardiovascular Diseases?

Authors:  Kouassi T Kouassi; Palanikumar Gunasekar; Devendra K Agrawal; Gopal P Jadhav
Journal:  J Cardiovasc Dev Dis       Date:  2018-09-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.